関連する実験動画
Updated: May 6, 2026

10:10
Quantifying Cognitive Decrements Caused by Cranial Radiotherapy
Published on: October 18, 2011
13.5K
ホルモン代用療法と認知:体系的レビューとメタ解析
E S LeBlanc1, J Janowsky, B K Chan
1Oregon Health Sciences University, 3181 SW Sam Jackson Park Rd, Mail Code HRC3, Portland, OR 97201-3098, USA. leblance@ohsu.edu
JAMA
|March 23, 2001
まとめ
ホルモン置換療法 (HRT) は,症状のある閉経後の女性の認知機能に利益をもたらす可能性がありますが,認知症を予防するための証拠は,研究の質によって制限されています. HRTを明確にするためにさらなる研究が必要である.
科学分野:
- 神経科学は神経科学である.
- エンドクリノロジー エンドクリノロジー
- ゲロントロジーはゲロントロジーの学科です.
背景:
- 観察研究は,ホルモン置換療法 (HRT) が認知機能低下と認知症のリスクを減らす可能性があることを示唆しています.
- 閉経後の女性の認知健康に対するHRTの影響に関して,矛盾する結果があります.
研究 の 目的:
- 健康な閉経後の女性の認知機能低下と認知症の予防のためのHRTに関する研究を体系的にレビューし,評価する.
主な方法:
- 関連する研究 (1966-2000年) をMEDLINE,HealthSTAR,PsychINFO,コクラン図書館で検索しました.
- 認知機能低下に関するランダム化対照試験とコホート研究,認知症リスクに関するコホート/症例対照研究を含む.
- JadadとUS Preventive Services Task Forceの基準を用いて研究の質を評価した.
主要な成果:
- HRTは,症状のある更年期女性では特定の認知機能 (言語記憶,警戒,推論,運動速度) を改善したが,無症状の女性ではそうではなかった.
- 観察研究のメタ解析では,HRTの使用は認知症のリスクの低下と関連していることが示された (OR,0.66;95%CI,0.53〜0.82).
- 潜在的なバイアスや混同因子を含む方法論的な限界は,認知症リスクの調査結果の解釈を制限します.
結論:
- HRTは,更年期症状を経験している女性にとって特定の認知上の利点を提供することができます.
- 観察データは,HRTによる認知症リスクの減少を示唆していますが,重要な方法論的制限は慎重に解釈する必要があります.
- 将来の研究は,HRTの特定の認知効果を明らかにし,研究設計の限界に対処することに焦点を当てなければなりません.
関連する概念動画
Long-term Depression
2.6K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.6K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
933
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
933
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Drug Dosing: Geriatric Patients
402
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
402
Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35

